German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

There have been no changes to the licensing and royalty agreements related to mRNA research that have netted the university ...

Warning comes after HHS Secretary Robert F. Kennedy Jr. announced cuts of nearly $500m in funding for mRNA vaccine projects, ...

Modern science emerged precisely to deal with the way everything can be manipulated – and scepticism over ‘facts’ goes all ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Estimated Vaccine Effectiveness ...

Jerome Adams, the U.S. Surgeon General under President Trump's first term, is criticizing his administration's cuts to mRNA vaccine research.

Neither UTMB nor Moderna has confirmed the nature of the project included in the announcement, or how much funding is being ...

Cancer vaccines in development rely on mRNA technology under attack by RFK Jr. “I am concerned that this could bleed over," ...